Volociximab

WikiDoc Resources for Volociximab
Articles
Most recent articles on Volociximab Most cited articles on Volociximab Review articles on Volociximab Articles on Volociximab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Volociximab Images of Volociximab Photos of Volociximab Podcasts & MP3s on Volociximab Videos on Volociximab
Evidence Based Medicine
Cochrane Collaboration on Volociximab Bandolier on Volociximab TRIP on Volociximab
Clinical Trials
Ongoing Trials on Volociximab at Clinical Trials.gov Trial results on Volociximab Clinical Trials on Volociximab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Volociximab NICE Guidance on Volociximab NHS PRODIGY Guidance FDA on Volociximab CDC on Volociximab
Books
Books on Volociximab
News
Volociximab in the news Be alerted to news on Volociximab News trends on Volociximab
Commentary
Blogs on Volociximab
Definitions
Definitions of Volociximab
Patient Resources / Community
Patient resources on Volociximab Discussion groups on Volociximab Patient Handouts on Volociximab Directions to Hospitals Treating Volociximab Risk calculators and risk factors for Volociximab
Healthcare Provider Resources
Symptoms of Volociximab Causes & Risk Factors for Volociximab Diagnostic studies for Volociximab Treatment of Volociximab
Continuing Medical Education (CME)
CME Programs on Volociximab
International
Volociximab en Espanol Volociximab en Francais
Business
Volociximab in the Marketplace Patents on Volociximab
Experimental / Informatics
List of terms related to Volociximab

Overview

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.

External link

• Official website